Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors.

Tatematsu, Daiki; Akao, Marwa; Park, Hyeongki; Iwami, Shingo; Ejima, Keisuke; Iwanami, Shoya

Tatematsu, Daiki; Akao, Marwa; Park, Hyeongki; Iwami, Shingo; Ejima, Keisuke; Iwanami, Shoya.

Afiliação

Tatematsu D; Division of Biological Science, School of Science, Nagoya University, Nagoya, Japan.
Akao M; Division of Biological Science, School of Science, Nagoya University, Nagoya, Japan.
Park H; interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
Iwami S; interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan; Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan; Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Ja
Ejima K; Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA.
Iwanami S; interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan. Electronic address: iwanami.iblab@bio.nagoya-u.ac.jp.

J Theor Biol ; 561: 111403, 2023 03 21.

Article em En | MEDLINE | ID: mdl-36586664

Assuntos

COVID-19; SARS-CoV-2; Humanos; Antivirais/uso terapêutico; Ensaios Clínicos Controlados Aleatórios como Assunto; Tamanho da Amostra; Resultado do Tratamento

Palavras-chave

COVID-19; Clinical trial; SARS-CoV-2; Virus dynamics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google